Home › Companies › TSHA

Taysha Gene Therapies

Market cap $1.30B 326.0M shares (10-Q, Nov 12, 2026) × $4.00 close Nov 17, 2026

Most recent annual filing: 2026-03-19

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. Second CNS gene therapy candidate1H 2027Second CNS gene therapy candidate, 1H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$423M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$32.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$423M cash, runway 2H 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Taysha Gene Therapies, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Taysha Gene Therapies (TSHA) - Scientific Deep Dive for TSHA-102 and Pipeline Products Taysha has de-risked the biology with solid video-adjudicated clinical data, secured written FDA alignment on an accelerated BLA pathway, and holds unencumbered global rights to a late-stage gene therapy with strong M&A appeal.
  2. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Dimmer Switch Holds The 100% response rate held and deepened at N=12 with ≥12 months follow-up, the pivotal trial overenrolled to N=17, and the safety database doubled to N=29 with zero treatment-related SAEs, further de-risking the thesis while the stock remains flat.
  3. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The $200M Raise on Strength The $200M raise-on-strength extends runway through BLA filing and into potential commercial launch, with bulge-bracket bookrunners and launch-prep use of proceeds signaling management conviction; clinical and regulatory thesis fully intact.
  4. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Deal Prints at $6.00 The offering cleared at the floor of the clean range at $6.00, resolving the financing overhang and funding the company through the BLA-to-launch window; sector sentiment rather than TSHA-specific concerns drove the discount.
  5. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Factory Gets a Landlord Locking in Catalent as commercial manufacturer at an FDA-licensed AAV facility with no tech transfer required shortens the CMC leg of the bear case while the stock trades below the offering price, widening the asymmetry.
  6. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The First Asterisk on a Clean Safety Record A single Grade 2 resolving peripheral sensory neuropathy adds a small crack to the safety leg of the bear case but does not reprice the thesis given the 100% response rate, fortified balance sheet, and pre-blessed regulatory pathway.
  7. Buy core UPDATE: Taysha Gene Therapies (TSHA) - Follow the Money, Finally RA Capital's 13G/A confirms a fully-loaded post-offering position of ~75.7M shares of economic exposure, answering the smart-money question and reinforcing the asymmetry while the stock trades below the $6.00 offering print on no company-specific news.
  8. Buy core UPDATE: Taysha Gene Therapies (TSHA) - The Factory Passed PPQ completed with all parameters meeting predefined specs and FDA-aligned comparability criteria, retiring the CMC leg of the bear case and enabling potential pooling of Part A data into the BLA, while the stock has fallen 29% on no negative company-specific news.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 22, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)